Category Archives: Business and Investments

Latest From Business and Investments

BIO Investor Forum Company Snapshot: NovelMed Therapeutics

NovelMed

NovelMed Therapeutics will be presenting at the upcoming BIO Investor Forum in October in San Francisco. Read below to learn more about their antibodies portfolio, what differentiates their company for the competition, and other interesting facts about the company. Company Snapshot What is your company’s lead product or technology? NovelMed has developed a portfolio of fully humanized monoclonal antibodies that selectively target only the disease-associated Complement System. As such, NovelMed’s antibodies are active against multiple Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

GAINing Ground in Antibiotics

GAIN

With the rise of antibiotic resistant “superbugs” in recent years, everyone agrees there is an urgent need to develop new and effective antibiotics. One measure designed to spur such development is the Generating Antibiotics Incentives Now (GAIN) Act, which was enacted last year. The law provides an additional five years of market exclusivity and priority FDA review for innovative antibiotics that target qualifying pathogens. Much of the current research in the field is being done Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , ,

Chinese In-Licensing Continues to Strengthen

Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are outpacing other forms of biotech deal-making in 2013. In fact, the number of in-licensing deals announced so far this year is more than the combined number of 2012 deals in out-licensing, JV/Alliance and M&A, according to BIO’s Industry Analysis research and GBI. This deal-making momentum bodes well for small and medium-sized biotech companies that have early-stage compounds under development in the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Company Snapshot: MAX BioPharma

maxbiopharma

Earlier this week, we featured a presenting company for our upcoming BIO Investor Forum event in San Francisco in our ‘company snapshot‘ feature. For our next post, we spoke to MAX BioPharma, who will be giving a presentation in our Discovery Company presentation track, which features companies in their Seed or Series A financing rounds, with under 25 million raised to date. Read on to learn more about this Discovery Company.   Company Snapshot What Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

CSBI: New Study Outlines Potential Impact of Three Promising Tax Proposals

shutterstock_26191726

Ernst & Young recently released a study to determine the potential impact of three tax proposals to help innovative small companies secure sustained private investment. The study models the direct, indirect, and induced impact that the three legislative proposals would have on investment and employment in small, R&D-intensive companies. Below is a summary of the proposals, as well as the potential impact if enacted: Proposal 1:  Section 469 R&D Partnership Structures. Reforming the passive activity Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,